NCT03982004: Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Skin
Additional Notes: Patients must have progression after 1+ therapies
Exclusions: Patients with known, active, or unstable central nervous system (CNS) metastases and/or carcinomatous meningitis; Stable metastases are permitted- see trial for details; Patients with prior immunotherapy of an anti-PD-1, anti-PD-L1/2, or CTLA-4
https://ClinicalTrials.gov/show/NCT03982004

Comments are closed.

Up ↑